NEPH (Nephros) Valuation Rank


NEPH Nephros Inc NEPH
63 GF Score
Price $3.40
GF Value $2.88
Valuation Modestly Overvalued
! 5 Warning Signs
View Full Analysis

What is Nephros Valuation Rank?

The Valuation Rank measures the current valuation of a business relative to other companies in the same industry and its own historical valuation. The companies are split in equal numbers and then ranked from 1 to 10, with 10 as the most undervalued and 1 as the most overvalued.

  1. Three factors:
    • Absolute valuation (medpsvalue) relative to current stock price, rank among all companies
    • Historical valuation over the past 10 years. Rank pe, ps, pocf, ev2ebit over their own historical values
    • Industry relative valuation
  2. Companies without enough data is not ranked
  3. Companies with negative earnings are ranked lower

These three factors are used to calculate the value score for every eligible company, with values from 1 to 10. The final ranked companies are split in equal numbers and ranked from 1 to 10, with 10 as the most undervalued, and 1 as the most overvalued. The numbers of companies in each rank are the same.

Nephros Valuation Rank Related Terms

NEPH
63GF Score
Nephros Inc NEPH
Valuation Rank is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Nephros (NEPH) Overvalued in 2026?

Based on GuruFocus' analysis, Nephros stock appears to be overvalued. The current stock price of $3.40 is trading 18.1% above its estimated GF Value™ of $2.88. GuruFocus considers Nephros to be Modestly Overvalued.

Key valuation signals for NEPH:

  • Valuation Rank:
  • GF Value™: $2.88 vs. price of $3.40 (18.1% above fair value)
  • GF Score™: 63/100 with 5 warning signs

No single metric tells the full story. See the NEPH stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Nephros Business Description

Other Exchanges NPJP:Germany
Address 380 Lackawanna Place, South Orange, NJ, USA, 07079
Nephros Inc is a commercial-stage company that develops and sells high-performance water solutions to the medical and commercial markets. In medical markets, it sells water filtration products and waterborne pathogen detection products. In commercial markets, the company manufactures and sells water filters that improve the taste and odor of water and reduce biofilm, bacteria, and scale build-up in downstream equipment. The company's subsidiary is engaged in the development of its second-generation hemodiafiltration system and other products focused on improving therapies for patients with renal disease. The company generates almost all of revenue from product sales and a small amount from royalty revenue and other revenues.
63GF Score

Get the complete analysis for NEPH

Valuation Rank is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$3.40
Price
$2.88
GF Value